Registered title, quoted from ClinicalTrials.gov
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 2
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07518173, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer;
Inclusion criterion 4
Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
Inclusion criterion 9
Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks or 5 half-lives prior to the first dose.
Exclusion criterion 1
ECOG performance status score of 0 or 1;
Inclusion criterion 8
Have at least one measurable target lesion as defined by RECIST v1.1;
Inclusion criterion 7
Diagnosed with another primary malignancy within 5 years before the first dose.
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07518173, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- Female patients aged ≥18 and ≤75 years at the time of signing the informed consent form;
- Expected survival time ≥12 weeks;
- Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer;
- Clear hormone receptor (HR) status;
- Agree to provide eligible tumor tissue specimens;
- Have at least one measurable target lesion as defined by RECIST v1.1;
- ECOG performance status score of 0 or 1;
- Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
- Organ function levels must meet the requirements;
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and must be non-lactating; all enrolled patients must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after treatment completion.
Exclusion Criteria:
- Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks or 5 half-lives prior to the first dose.
- Previously received ADC drug therapy with camptothecin derivatives as toxins.
- History of severe cardiovascular or cerebrovascular disease within six months before screening.
- Concomitant pulmonary disease resulting in severely impaired lung function.
- History of interstitial lung disease (ILD)/interstitial pneumonia requiring corticosteroid therapy, etc.
- QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias.
- Diagnosed with another primary malignancy within 5 years before the first dose.
- Newly developed deep vein thrombosis within 14 days before screening.
- Hypertension poorly controlled by antihypertensive medications.
- Patients with active central nervous system metastases.
- History of severe allergic reactions to recombinant humanized antibodies or any excipient or component of BL-M07D1.
- History of autologous or allogeneic stem cell transplantation or organ transplantation.
- Previously received anthracycline therapy exceeding the prescribed dose limit.
- Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection.
- Severe infection within 4 weeks prior to the first use of the study drug, etc.
- Patients with large serous cavity effusions, serous cavity effusions with obvious symptoms, or poorly controlled serous cavity effusions.
- Receiving systemic corticosteroid therapy >10 mg/day prednisone or equivalent prior to randomization, etc.
- Presence of severe neurological or psychiatric disorders.
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent.
- Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.
- Subjects planning to receive or having received live vaccines within 28 days before the first dose.
- Presence of other serious physical conditions, abnormal laboratory findings, or poor compliance that may increase the risk of participating in the study, interfere with study results, or make the patient unsuitable for participation in the study in the investigator's opinion.
Quoted from ClinicalTrials.gov, NCT07518173, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07518173, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.